Immunic, Inc.
IMUX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $100,175 | $66,480 | $44,547 | $226,357 |
| - Cash | $35,668 | $46,674 | $106,745 | $86,863 |
| + Debt | $1,004 | $1,334 | $1,563 | $992 |
| Enterprise Value | $65,511 | $21,140 | -$60,635 | $140,486 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$97,918 | -$99,112 | -$86,441 | -$91,580 |
| % Margin | – | – | – | – |
| Net Income | -$100,507 | -$93,612 | -$120,407 | -$92,945 |
| % Margin | – | – | – | – |
| EPS Diluted | -1 | -2.11 | -3.78 | -3.92 |
| % Growth | 52.6% | 44.2% | 3.6% | – |
| Operating Cash Flow | -$84,766 | -$70,828 | -$65,144 | -$83,233 |
| Capital Expenditures | -$264 | -$334 | -$112 | -$67 |
| Free Cash Flow | -$85,030 | -$71,162 | -$65,256 | -$83,300 |